Effect of lanthanum carbonate on urine biomarkers in chronic kidney disease patients.

Effect of lanthanum carbonate on urine biomarkers in chronic kidney disease patients. - Effect of lanthanum carbonate in CKD patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017030

Enrollment

Registered

2015-05-31

Start date

2015-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Treatment for CKD + Oral administration of lanthanum carbonate hydrate Treatment for CKD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD patients (eGFR<30) 4.5mgdL < serum phosphorus < 5.5mg/dL

Exclusion criteria

Exclusion criteria: Diabetes Pregnancy After renal transplantation patients with contraindicated in the attached document of lanthanum carbonate.

Design outcomes

Primary

Measure	Time frame
The rate of change of the urinary biomarkers (L-FABP, NGAL, IL-18, KIM-1) after 6 months.	—

Countries

Japan

Contacts

Public ContactAyumu Nakashima

Hiroshima University Hospital Department of Nephrology

ayumu@hiroshima-u.ac.jp082-257-1506

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026